FOXO1 and neoplasm: Although molecular testing for PAX3/7–FOXO1 fusions is becoming increasingly common in North America and Europe, not all RMS cases have FOXO1 fusion molecular testing due to limited available resources, an absence of ARMS histology in the tumor, and other practical reasons such as lack of available resources.